Month: February 2007
-
By Christopher P. Singer — In a February 7, 2007 Wall Street Journal article entitled: "Small Firms Seek to Profit From Drug Giants' Castoffs" (subscription required), Jeanne Whalen discusses a drug development strategy that is more frequently being employed by small drug companies. In particular, smaller companies employing this strategy enter into agreements…
-
By Christopher P. Singer — In a February 5, 2007 press release Cell Genesys announced that it has secured a Committed Equity Financing Facility (CEFF) of up to $75 million with institutional investor Kingsbridge Capital Limited. The financing will derive from the sale of newly issued common shares of stock from Cell Genesys…
-
By Christopher P. Singer — In a February 5, 2007 press release Regeneron Pharmaceuticals, Inc. announced that it has entered into a non-exclusive license agreement with AstraZeneca involving Regeneron's VelocImmune® antibody technology. The license includes an upfront $20 million payment to Regeneron in addition to as many as five additional annual payments of…
-
West Legalworks® is offering a webcast entitled: "Rethinking Patent License Agreements in the Wake of MedImmune v. Genentech" on February 6, 2007 from 12:00-1:30 PM (EST). Speakers Brian Kacedon and Kathleen Daley will discuss patent license provisions and strategies in view of the MedImmune decision. According to Thomson-West, the speakers will also address the following…
-
By Kevin Noonan — In several recent posts, I have taken the position that patents, particularly patents on genes and recombinant or transgenic non-human organisms, have been vital to America's preeminence in the biotechnology and pharmaceutical industries. A recent Washington Post story by Joseph Fuller and Brock Reeve supports this view. The statistics…
-
February 27-28, 2007 – Patent Portfolio Management (American Conference Institute) – New York, NY March 25-29, 2007 – American Chemical Society National Meeting – Chicago, IL April 16-18, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources Group) – Orlando, FL
-
Pfizer Earns One More Victory in Norvasc Litigation By Robert Dailey — This week Pfizer won another courtroom battle against generic drug manufacturer Synthon in the companies' ongoing dispute over Pfizer's drug Norvasc. The District Court held two Synthon patents, U.S. Patent Nos. 6,653,481 and 6,858,738 unenforceable due to inequitable conduct. Pfizer had…
-
By Christopher P. Singer — In two separate collaboration agreements announced on January 31, 2007, AstraZeneca has partnered with Argenta Discovery in an effort to identify and develop improved bronchodilators, and with Palatin Technologies to develop small molecule obesity drugs. Argenta's press release states that the deal includes a $21 million payment from…
-
By Jason Derry — The Thailand government recently announced that it has issued two more compulsory licenses for generic versions of patented drugs. One of the drugs is Plavix, a heart disease drug made by Bristol-Myers Squibb and Sanofi-Aventis. The other drug is Kaletra, an HIV/AIDS drug made by Abbott Laboratories. The licenses follow…
Patent Docs 